Rheumatology Patient Registry and Biorepository
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT04402086
- Status
- Recruiting
Conditions
- Adult Onset Still Disease
- Ankylosing Spondylitis
- Antiphospholipid Syndrome
- Behcet Disease
- Dermatomyositis
- Giant Cell Arteritis
- Lyme Disease
- Mixed Connective Tissue Disease
- Polymyalgia Rheumatica
- Polymyositis
- Psoriatic Arthritis
- Reactive Arthritis
- Rheumatic Diseases
- Rheumatoid Arthritis
- Sarcoidosis
- Scleroderma
- Sjogren's Syndrome
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Undifferentiated Connective Tissue Diseases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Accepted
Study Details
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Key Dates
- Start date
- Aug 4, 2020
- Status verified
- Feb 2026
- Primary completion
- Jun 1, 2030
- Completion
- Jun 1, 2030
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: BiorepositoryParticipants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
Primary Outcome Measure
Correlate outcomes and biomarkers of rheumatic diseases [ Time Frame: 10 years ]
Central Contacts
- Stephanie Perez, MS, BS203-737-5571
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | 203-737-5571 Monique Hinchcliff, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New Haven, CT
By research site
Related Studies
- Cardiac Sarcoidosis Randomized TrialPHASE3 · Recruiting · Ottawa Heart Institute Research Corporation · New Haven, Connecticut
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Aurora, Colorado
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyPHASE3 · Enrolling By Invitation · argenx · Phoenix, Arizona